View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Dashboards
  2. Surveys
May 31, 2021

Decentralised clinical trials helped gain access to patient pool during pre-pandemic period, finds GlobalData survey

The topmost reason that organisations used decentralised clinical trials (DCTs) during the pre-pandemic period was to have an improved access to a suitable patient pool.

This reason garnered 21% votes in a survey, titled Coronavirus Survey on COVID-19 and Decentralized Clinical Trials, carried out by GlobalData between 4 June 2020 and 22 June 2020.

The survey fielded the question on why decentralised trials/virtual clinical trials were used.

DCTs helped gain access to patient pool during pre-pandemic period

Reasons Why Pre-pandemic Adopters Chose Decentralised Trials

This survey found that 16% of the firms used DCTs because it enables different study designs, relying more on real world data and higher data volume from devices than fixed investigator visit primary endpoints.

Greater participation by patients in clinical trial was listed as the third reason, which figured at 12%. Increased participation by sites in clinical trials stood at 11%.

Improved data quality due to near time data collection and automation figured as the next reason with 10%, while reduction in trial cost garnered 8% votes.

Three reasons that gained 7% votes were reduction in trial timeline, less technical complexity in running studies, and less technical complexity using study-related systems.

DCTs remove the geography problem that hinders traditional trials, thereby enabling recruitment of patients anywhere without the need to visit a site.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology